| 臺大學術典藏 |
2021-03-11T08:34:18Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:29:32Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:27Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-08T12:07:09Z |
Circulating exosomal integrin �]3 is associated with intracranial failure and survival in lung cancer patients receiving cranial irradiation for brain metastases: A prospective observational study
|
Chen G.-Y.; Cheng J.C.-H.; Chen Y.-F.; Yang J.C.-H.; Feng-Ming Hsu |
| 臺大學術典藏 |
2021-02-23T08:26:23Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.;Yang J.C.-H.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Lin Z.-Z.;Lan K.-H.;Cheng A.-L.;Sung-Hsin Kuo; Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-23T08:26:16Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Sung-Hsin Kuo;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; SUNG-HSIN KUO; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2021-02-23T08:26:10Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Sung-Hsin Kuo; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-01-08T03:40:19Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 國立成功大學 |
2021 |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
Yang, J.C.-H.;Reckamp, K.L.;Kim, Y.-C.;Novello, S.;Smit, E.F.;Lee, J.-S.;Su, W.-C.;Akerley, W.L.;Blakely, C.M.;Groen, H.J.M.;Bazhenova, L.;Carcereny, Costa E.;Chiari, R.;Hsia, T.-C.;Golsorkhi, T.;Despain, Despain D.;Shih, D.;Popat, S.;Wakelee, H. |
| 臺大學術典藏 |
2020-12-24T03:18:47Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Chia-Lin Hsu;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; CHIA-LIN HSU; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-12-24T03:18:46Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Chia-Lin Hsu;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-12-02T02:34:03Z |
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
|
Su K.-Y.; Chen H.-Y.; Li K.-C.; Kuo M.-L.; Yang J.C.-H.; Chan W.-K.; Ho B.-C.; Chang G.-C.; Shih J.-Y.; Yu S.-L.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:34:00Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A. |
| 臺大學術典藏 |
2020-12-02T02:33:55Z |
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
|
Huang C.-P.; Tsai M.-F.; Chang T.-H.; Tang W.-C.; Chen S.-Y.; Lai H.-H.; Lin T.-Y.; Yang J.C.H.; PAN-CHYR YANG; Shih J.-Y.; Lin S.-B. |
| 臺大學術典藏 |
2020-12-02T02:33:46Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Wang J.-Y.; Ruan S.-Y.; Yu C.-J.; Yang J.C.H.; PAN-CHYR YANG; Shih J.-Y.; Tsai T.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:45Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.;Hsieh M.-S.;Wu S.-G.;Chang Y.-L.;Shih J.-Y.;Liu Y.-N.;Tsai M.-F.;Tsai T.-H.;Yu C.-J.;Yang J.C.-H.;PAN-CHYR YANG; Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:33:39Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Lin Y.-T.;Wang Y.-F.;Yang J.C.-H.;Yu C.-J.;Wu S.-G.;Shih J.-Y.;Pan-Chyr Yang; Lin Y.-T.; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:33:33Z |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
Hsu C.-L.; Chen J.-H.; Chen K.-Y.; Shih J.-Y.; Yang J.C.H.; Yu C.-J.; Pan-Chyr Yang; Hsu C.-L.; Chen J.-H.; Chen K.-Y.; Shih J.-Y.; Yang J.C.H.; Yu C.-J.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:33:26Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Pan-Chyr Yang; Shih J.-Y.; Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; PAN-CHYR YANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-12-02T02:33:23Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu K.-L.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Pan-Chyr Yang; Chen L.-Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:23Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; Yu C.-J.; Pan-Chyr Yang; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y.; Wu S-G.; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; Yu C.-J.; PAN-CHYR YANG; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:15Z |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors
|
Chang I.-S.; Jiang S.S.; Yang J.C.-H.; Su W.-C.; Chien L.-H.; Hsiao C.-F.; Lee J.-H.; Chen C.-Y.; Chen C.-H.; Chang G.-C.; Wang Z.; Lo F.-Y.; Chen K.-Y.; Wang W.-C.; Chen Y.-M.; Huang M.-S.; Tsai Y.-H.; Su Y.-C.; Hsieh W.-S.; Shih W.-C.; Shieh S.-H.; Yang T.-Y.; Lan Q.; Rothman N.; Chen C.-J.; Chanock S.J.; Pan-Chyr Yang; Hsiung C.A.; Chang I.-S.; PAN-CHYR YANG et al. |
